Catalyst Biosciences

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of novel medicines to address serious medical conditions. The company was founded on March 7, 1997 and is headquartered in South San Francisco, CA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis). The firm operates through the BC and Gyre segments. The company was founded on March 7, 1997 and is headquartered in San Diego, CA.

Board is Committed to Maximizing the Amount of Cash the Company Distributes to Stockholders

Catalyst Biosciences Announces Plan to Distribute Cash to Stockholders

Here is how Catalyst Biosciences, Inc. (CBIO) and Humana (HUM) have performed compared to their sector so far this year.

Has Catalyst Biosciences (CBIO) Outpaced Other Medical Stocks This Year?

Geovax Labs

Medavail Holdings Inc

Rhythm Pharmaceuticals

View

Penny stocks are red hot right now if you know where to… The post 5 Penny Stocks To Watch With High Short Interest, Are They A Buy Now? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Watch With High Short Interest, Are They A Buy Now?

Didi Global

Which penny stocks are you watching right now? The post Hot Penny Stocks to Buy This Week?

Hot Penny Stocks to Buy This Week? 3 to Watch

Endeavour Silver

Thimble Point Acquisition Corp

Penny stocks with unusual options activity today. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 3 With Unusual Options Activity To Watch

Catalyst Biosciences (CBIO) stock is rocketing higher on Monday after announcing the sale of its protease medicines portfolio. The post Why Is Catalyst Biosciences (CBIO) Stock Soaring 170% Today?

Why Is Catalyst Biosciences (CBIO) Stock Soaring 170% Today?

Catalyst Biosciences Inc (NASDAQ: CBIO) shares are trading higher by 180.26% at $1.06 after the company announced it sold its complement portfolio for $60 million. A definitive asset purchase and sale agreement with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) has allowed Vertex to acquire.

Why Catalyst Biosciences Shares Are Skyrocketing Today

Catalyst Biosciences Inc (NASDAQ: CBIO) has agreed to sell its portfolio of protease medicines that regulate complement to Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) for $60 million. "This sale is part of the ongoing strategic process that we announced in.

Catalyst Biosciences Stock More Than Doubles After Assets Sale To Vertex

Cybin

Jaguar Health

Kala Pharmaceuticals

Penny stocks under $1 to watch right now. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 4 To Watch Under $1

SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it has signed a definitive asset purchase and sale agreement with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) under which Vertex has acquired Catalyst's portfolio of protease medicines that regulate complement, including CB 2782-PEG, for $60 million in cash.

Catalyst Biosciences Sells Complement Portfolio for $60 Million

SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the first quarter ended March 31, 2022.

Catalyst Biosciences Reports First Quarter 2022 Operating & Financial Results

SOUTH SAN FRANCISCO, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update.

Catalyst Biosciences Reports Fourth Quarter and Year-end 2021 Operating & Financial Results and Provides a Corporate Update

SOUTH SAN FRANCISCO, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the company has regained full rights to CB 2782-PEG, a C3-degrader for the treatment of dry AMD (dAMD). Under the terms of the agreement, Biogen has returned the rights for further development on CB 2782-PEG and has ended the collaboration on other potential AMD treatments.

Catalyst Biosciences Regains Rights to CB 2782-PEG for the Treatment of Dry AMD Expands CBIO's Complement Portfolio in Ophthalmology

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced it has retained Perella Weinberg Partners (PWP) as a financial advisor to assist the Company in exploring strategic alternatives.

Catalyst Biosciences Engages Perella Weinberg Partners to Assist the Company in Exploring Strategic Alternatives

SOUTH SAN FRANCISCO, Calif., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) for CB 4332 for the treatment of Complement Factor I (CFI) deficiency (CFID).

Catalyst Biosciences Receives Rare Pediatric Disease Designation for CB 4332 for the Treatment of CFI Deficiency

Catalyst Biosciences, Inc. (CBIO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Catalyst Biosciences, Inc. (CBIO) Upgraded to Buy: Here's What You Should Know

SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that members of its executive management team will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference, being held November 29-December 2, 2021.

Catalyst Biosciences to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

Catalyst Biosciences Inc (NASDAQ: CBIO) has decided to halt the clinical development of MarzAA (engineered FVIIa) and focus solely on complement programs and protease medicines platforms. MarzAA was under development for Factor VII deficiency, a blood clotting disorder.

What Is Happening With Catalyst Biosciences Shares Today?

Reports Third Quarter 2021 Operating & Financial Results Reports Third Quarter 2021 Operating & Financial Results

Catalyst Biosciences Announces Change in Corporate Strategy

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that Grant Blouse, Ph.D., chief scientific officer, will present at two upcoming scientific conferences, the 5th Complement-based Drug Development Summit, being held October 26-28, 2021, and the American Society for Biochemistry and Molecular Biology's (ASBMB) Serine Proteases in Pericellular Proteolysis and Signaling Virtual Meeting, being held October 28-30, 2021. Catalyst will provide an overview of the Company's ProTUNE™ platform, and its ability to engineer Complement Factor I (CFI) for potency and specificity in complement-mediated disorders.

Catalyst Biosciences Announces CFI Variant Presentations at Two Upcoming Scientific Conferences

Catalyst Biosciences, Inc. (CBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Catalyst Biosciences, Inc. (CBIO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

SOUTH SAN FRANCISCO, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that its chief financial officer, Clinton Musil, has resigned for personal reasons effective October 29, 2021. Seline Miller, the Company's controller, has been promoted to senior vice president, finance and will serve as interim chief financial and principal accounting officer while the Company initiates a search for a successor.

Catalyst Biosciences Announces Chief Financial Officer Transition

The FDA has granted Orphan Drug Disease Designation to Catalyst Biosciences Inc's (NASDAQ: CBIO) Marzeptacog alfa (activated), or MarzAA, for Factor VII Deficiency (FVIID).  Factor VII deficiency is a blood clotting disorder that causes excessive or prolonged bleeding after an injury or surgery.

Catalyst Biosciences' Lead Candidate Secures Orphan Drug Tag For Blood Clotting Disorder

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Disease Designation (ODD) for its lead product candidate, subcutaneous Marzeptacog alfa (activated), or MarzAA, for the treatment of Factor VII Deficiency (FVIID). MarzAA was previously granted ODD and Fast Track Designation (FTD) for treatment of Hemophilia A/B with inhibitors and FTD for the treatment of FVIID.

FDA Grants Catalyst Biosciences Orphan Drug Designation for MarzAA for the Treatment of Factor VII Deficiency

SOUTH SAN FRANCISCO, Calif., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that a fireside chat including members of its executive management team will be broadcast as part of the Cantor Global Healthcare Conference at 10:00 am ET on Wednesday, September 29, 2021.

News for Catalyst Biosciences Stock (CBIO)